Premium
O1‐10‐01: Gantenerumab Treatment Reduces Biomarkers of Neuronal and Synaptic Degeneration in Alzheimer’s Disease
Author(s) -
Blennow Kaj,
Nikolcheva Tania,
Lasser Robert A.,
Dukart Juergen,
Rabe Christina,
Volz Dietmar,
Scheltens Philip
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.346
Subject(s) - neurogranin , biomarker , medicine , cerebrospinal fluid , placebo , neuroinflammation , oncology , dementia , neurodegeneration , tau protein , alzheimer's disease , gastroenterology , pathology , disease , biology , biochemistry , alternative medicine , protein kinase c , enzyme
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom